Irbesartan
Irbesartan (INN) /ɜːrbəˈsɑːrtən/ is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. It was developed by Sanofi Research (now part of Sanofi-Aventis). It is jointly marketed by Sanofi-Aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.
Starting at
Product Description
| 2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one |
| Trade names | Avapro |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a698009 |
| Licence data | EMA:Link, US FDA:link |
| Pregnancy category |
D (Au) |
| Legal status | S4 (Au), POM (UK), ℞-only (U.S.) |
| Routes of administration |
Oral |
| Bioavailability | 60–80% |
| Protein binding | ~90% |
| Metabolism | Hepatic (CYP2C9) |
| Biological half-life | 11–15 hours |
| Excretion | Renal 20%, faecal 65% |
| CAS Number | 138402-11-6 |
| ATC code | C09CA04 |
| PubChem | CID: 3749 |
| IUPHAR/BPS | 589 |
| DrugBank | DB01029 |
| ChemSpider | 3618 |
| UNII | J0E2756Z7N |
| KEGG | D00523 |
| ChEBI | CHEBI:5959 |
| ChEMBL | CHEMBL1513 |
| Formula | C25H28N6O |
| Molecular mass | 428.53 g/mol |
| SMILES[show] | |
| InChI[show] | |
